Which laboratory tests should be ordered on the requisition form for a cervical cytology (Pap smear) with high‑risk HPV DNA co‑testing?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Laboratory Tests for Cervical Cytology with HPV Co-Testing

For cervical cancer screening with high-risk HPV DNA co-testing, order: (1) Cervical cytology (Pap test) and (2) High-risk HPV DNA testing for 13-14 oncogenic HPV types on the laboratory requisition form.

Specific Tests to Order

Primary Tests Required

Both tests should be ordered together for women aged ≥30 years 1, 2:

  • Cervical cytology (Pap test) - using either liquid-based or conventional cytology methods
  • High-risk HPV DNA test - detecting 13-14 high-risk HPV types (16,18,31,33,35,39,45,51,52,56,58,59,66,68)

FDA-Approved HPV Tests

The laboratory requisition should specify one of these validated high-risk HPV DNA tests 1:

  • Hybrid Capture 2 High-Risk HPV DNA test (Qiagen) - detects 13 high-risk types
  • Cervista HPV High-Risk test (Hologics) - detects 13-14 high-risk types
  • BD Onclarity HPV Assay 3
  • Cobas 4800 HPV Test 3
  • Abbott RealTime High Risk HPV 3
  • Xpert HPV 3

Age-Specific Ordering Guidelines

Women Aged 30-65 Years

Co-testing (cytology + HPV) every 5 years is the preferred approach 2. The requisition should include:

  • Cervical cytology
  • High-risk HPV DNA testing

This combination allows for 5-year screening intervals when both tests are negative 1.

Women Aged 21-29 Years

Order cytology alone every 2 years 2. HPV testing should NOT be ordered for routine screening in this age group 1. The only exception is using HPV testing for triage of ASC-US cytology results in women ≥21 years 1.

Critical Specifications for the Lab Requisition

What NOT to Order

Do not order low-risk HPV testing - only high-risk types are clinically useful for screening 1, 4. Testing for low-risk HPV types (6,11) has no role in cancer screening and may cause unnecessary patient anxiety 4.

Optional Add-On Testing

HPV 16/18 genotyping can be added as reflex testing for specific triage situations 2:

  • When cytology is negative but high-risk HPV is positive in women ≥30 years
  • This helps determine whether immediate colposcopy is needed (HPV 16/18 positive) or 12-month follow-up is appropriate (other high-risk types)

However, HPV 16/18 genotyping should NOT be used to triage women with ASC-US who are already high-risk HPV positive - these women should proceed directly to colposcopy 2.

Common Pitfalls to Avoid

  1. Don't order HPV testing alone without cytology for primary screening - this is not recommended 1. Co-testing provides optimal sensitivity and specificity.

  2. Don't order HPV testing in women <21 years - even if sexually active, this leads to overdetection of transient infections and unnecessary interventions 1, 2, 1.

  3. Ensure the lab uses validated assays - only FDA-approved tests meeting international validation criteria should be used 3, 5. The test must detect at least 13-14 high-risk HPV types with clinical sensitivity for CIN2+ ≥90% 6.

  4. Specify collection method - clinician-collected cervical specimens are preferred over self-collected vaginal specimens for co-testing, as self-collected samples require different follow-up intervals 7.

Test Performance Characteristics

High-risk HPV testing has approximately 25% higher sensitivity but 10% lower specificity compared to cytology alone for detecting high-grade lesions 4. The combination of both tests (co-testing) provides:

  • 98.1% sensitivity for CIN3+ with HPV testing 8
  • 96.5% specificity with cytology 8
  • Very high negative predictive value when both are negative, justifying extended 5-year screening intervals 4

The requisition form should clearly indicate both tests are needed to achieve this optimal balance of sensitivity and specificity for detecting cervical precancer.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.